HHS: Providers should order antibody therapies directly from distributor

Feb 22, 2021 - 03:02 PM
HHS Logo web sized 900x400

Authorized health care providers should now order the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab directly from the sole distributor, AmerisourceBergen Corp., the Department of Health and Human Services announced Friday.

HHS’ Office of the Assistant Secretary for Preparedness and Response will no longer allocate the therapies to health departments because the drugs are no longer in short supply, the agency said, noting that the products remain free of charge to requesting sites. “HHS will continue to monitor all direct orders, and we retain the capacity to resume allocation of these and future therapies if needed.” For more on the direct ordering process, see the ASPR guide.

The Food and Drug Administration in November issued emergency use authorizations for bamlanivimab and casirivimab/imdevimab to treat certain COVID-19 outpatients at risk for severe disease.

Related News Articles

Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
OSHA proposes removing remaining requirements of its COVID-19 emergency temporary standard
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
RFK Jr. says CDC will no longer recommend COVID-19 vaccine for healthy children, pregnant women
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
FDA to limit COVID-19 vaccine to people over 65, others at high risk for serious illness
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
Study finds driving with COVID-19 raises crash risk by 25%
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…